389 related articles for article (PubMed ID: 11454733)
21. Clearance of linezolid via continuous venovenous hemodiafiltration.
Mauro LS; Peloquin CA; Schmude K; Assaly R; Malhotra D
Am J Kidney Dis; 2006 Jun; 47(6):e83-6. PubMed ID: 16731287
[TBL] [Abstract][Full Text] [Related]
22. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
23. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
24. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
25. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method.
Toutain J; Boselli E; Djabarouti S; Allaouchiche B; Xuereb F; Bernadou JM; Ba B; Saux MC; Breilh D
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):145-50. PubMed ID: 15556527
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
[TBL] [Abstract][Full Text] [Related]
27. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
[TBL] [Abstract][Full Text] [Related]
28. Impact of ontogeny on linezolid disposition in neonates and infants.
Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
[TBL] [Abstract][Full Text] [Related]
29. Ocular penetration of linezolid after oral administration in rabbits.
Saleh M; Lefevre S; Bourcier T; Prevost G; Gaucher D; Speeg-Schatz C; Jehl F
J Ocul Pharmacol Ther; 2011 Jun; 27(3):243-6. PubMed ID: 21510740
[TBL] [Abstract][Full Text] [Related]
30. Bone tissue and plasma concentrations of linezolid and vancomycin in rabbits with prosthesis-related infection due to MRSA.
Swoboda S; Helbig L; Kommerell M; Simank HG; Kees F; Geiss HK; Hoppe-Tichy T; Schröder K
Pharmazie; 2009 Jun; 64(6):407-9. PubMed ID: 19618680
[TBL] [Abstract][Full Text] [Related]
31. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
32. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
Yi P; Hadden C; Kulanthaivel P; Calvert N; Annes W; Brown T; Barbuch RJ; Chaudhary A; Ayan-Oshodi MA; Ring BJ
Drug Metab Dispos; 2010 Apr; 38(4):554-65. PubMed ID: 20075192
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration.
Horcajada JP; Atienza R; Sarasa M; Soy D; Adán A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):550-2. PubMed ID: 19109336
[TBL] [Abstract][Full Text] [Related]
34. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
[TBL] [Abstract][Full Text] [Related]
36. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
37. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
38. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
[TBL] [Abstract][Full Text] [Related]
39. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?
Hamilton R; Thai XC; Ameri D; Pai MP
J Antimicrob Chemother; 2013 Mar; 68(3):666-73. PubMed ID: 23160755
[TBL] [Abstract][Full Text] [Related]
40. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
